An Overview on Neonatal Jaundice Prema V.1,*, Rizwan K. Mohamed2, Tamilarasan S.2 1Department of Pharmaceutical Chemistry, K. K. College of Pharmacy, Gerugambakkam, Chennai -128, Tamil Nadu, India 2Department of Pharmacy Practice, K. K. College of Pharmacy, Gerugambakkam, Chennai - 128, Tamil Nadu, India *Corresponding Author E-mail: premapharmchemistry@gmail.com
Online Published on 04 October, 2023. Abstract A significant proportion of term and preterm infants develop neonatal jaundice. Jaundice in a healthy term infant is the most common reason for readmission to hospital. Jaundice is caused by a significant increase in serum bilirubin levels, largely due to the breakdown of red blood cells. Bilirubin is transported in the blood as 'unconjugated' bilirubin, largely bound to albumin. The bilirubin is converted into a conjugated form by the liver, which is excreted in the bile. Very high levels of unconjugated bilirubin led to neurotoxicity. In most infants, severe hyperbilirubinemia is caused due to an increase in bilirubin production (e.g., due to haemolysis) and thus reducing bilirubin production is a rational approach for its management. The situation can become critical in infants with an associated impaired bilirubin elimination mechanism as a result of a genetic deficiency and polymorphism. The simplest way to reduce bilirubin levels is by phototherapy. Current management of jaundice in the UK is guided by the NICE guideline.1 Top Keywords Neonatal jaundice, Infants, Bilirubin, Conjugation, Phototherapy. Top |